Roger Hampel
Photo Credit: FC Barcelona
The Barça Innovation Hub (BIHUB) has made a significant stride in its venture into the biotech industry by investing in Rimbarlat, a promising start-up focused on developing cutting-edge therapies to accelerate muscular regeneration. This investment highlights FC Barcelona’s commitment to enhancing sports science and medicine, particularly for elite athletes recovering from acute injuries.
FC Barcelona's Medical Facilities to Host Clinical Trials
As part of the partnership, Rimbarlat will conduct clinical trials of its groundbreaking therapies at FC Barcelona’s medical facilities in the coming months. The club’s medical professionals will provide hands-on support, leveraging their expertise in sports medicine to facilitate the development and refinement of these treatments. This collaboration is expected to greatly accelerate the advancement of Rimbarlat’s therapies, offering potentially transformative results in the world of sports injury recovery.
Cutting Recovery Time by 50%: A Game Changer in Sports Medicine
Rimbarlat’s innovative approach has already demonstrated promising results in early studies, with potential to reduce recovery times by up to 50%. This accelerated healing process could revolutionize how professional sports clubs manage athletes' injuries, particularly those involving muscles. Such advancements are invaluable in the high-performance world of elite sports, where every day of recovery can affect an athlete’s career and a club’s success.
BIHUB recognized Rimbarlat’s potential, particularly in regenerative medicine, seeing its value not only for FC Barcelona but for the broader football community and professional sports industry. With this partnership, FC Barcelona aims to solidify its leadership position in sports medicine innovation.
Rimbarlat: A Rising Star in Barcelona’s Biotech Scene FC Barcelona Rimbarlat
Founded in 2020 by Luis Santiago and Jorge Martín, Rimbarlat is a Barcelona-based biotech company specializing in therapies designed to improve muscular regeneration. Operating out of Cosymbio Labs in Barcelona’s Poblenou district, the company is focused on technological science and biomedicine. Its work is grounded in applied research, with an emphasis on creating innovative solutions that have practical applications for elite athletes and the broader medical community.
BIHUB's Expanding Portfolio of Start-ups
Rimbarlat marks the seventh start-up investment for BIHUB, joining a growing portfolio of innovative companies. Previous BIHUB collaborations include Visualfy, which promotes accessibility for the deaf and hard of hearing; OLIVER, a platform that enhances data management for grassroots sports; Onalabs, which measures biometric data through sweat analysis; CeleBreak, an app connecting amateur footballers; Made of Genes, a leader in molecular studies and personalized health; and Fyxbody, a solution for planning training and recovery sessions.
Pushing the Boundaries of Sports Innovation
BIHUB’s continued investment in start-ups reflects FC Barcelona’s dedication to staying at the forefront of sports innovation. By supporting emerging companies with high-potential technologies, the club is actively shaping the future of sports medicine and performance enhancement. In return, these companies benefit from FC Barcelona’s vast brand assets, cutting-edge facilities, and access to top-tier athletes.
This dynamic synergy has not only strengthened Barça’s leadership in sports science but has also bolstered Barcelona’s reputation as a hub for technological and biomedical innovation. The club’s strategic investments in biotech firms like Rimbarlat contribute to the growth of the local economy, fostering talent within Catalonia and attracting global experts to the region.
Statements from Key Leaders
Joan Laporta, President of FC Barcelona, emphasized the importance of muscular injury research:“Deepening our knowledge of recovery from muscular injuries is becoming a key focus for the FC Barcelona Medical Services as we face an ever-expanding sporting calendar. Our investment in Rimbarlat ensures that the Club remains at the forefront of research, helping us offer more efficient treatment to our athletes. We hope this study will build on the positive results of the early phases and enable us to develop therapies that significantly shorten recovery times.”
Luis Santiago, CEO of Rimbarlat, echoed the excitement surrounding the partnership:“Myself and my partner Jorge Martín are delighted by this strategic alliance with FC Barcelona. The club is committed to deepening knowledge in this field and supporting biotech businesses. We are convinced that the human and technical support Barça brings will help us achieve our goals, leading to a sea-change in how we treat sporting injuries.”
Comments